NAIROBI, Kenya – The Pharmacy and Poisons Board (PPB) has issued an urgent quarantine order for a specific batch of Flurasted 500 (5-Fluorouracil) Injection, a drug widely used in cancer treatment.
The affected batch, identified as Batch No. HHP24017, was manufactured by Halsted Pharma Private Limited in India.
This action follows a market complaint about the drug’s appearance, raising concerns about its quality and safety.
In response, the PPB has directed all pharmaceutical outlets, healthcare facilities, and healthcare professionals to immediately quarantine the product.
Distribution, sale, and use of the batch have been prohibited until further notice.
The PPB is also urging members of the public to cooperate by reporting any adverse reactions or suspected cases of substandard medication.
Such reports can be made at healthcare facilities or directly to the Board.
Flurasted 500 is an essential medication in the management of cancer, and its safety is critical for patients undergoing treatment.
The Board’s swift action highlights the importance of maintaining rigorous quality control in the pharmaceutical supply chain.
The affected batch, identified as Batch No. HHP24017, was manufactured by Halsted Pharma Private Limited in India.
This action follows a market complaint about the drug’s appearance, raising concerns about its quality and safety.
In response, the PPB has directed all pharmaceutical outlets, healthcare facilities, and healthcare professionals to immediately quarantine the product.
Distribution, sale, and use of the batch have been prohibited until further notice.
The PPB is also urging members of the public to cooperate by reporting any adverse reactions or suspected cases of substandard medication.
Such reports can be made at healthcare facilities or directly to the Board.
Flurasted 500 is an essential medication in the management of cancer, and its safety is critical for patients undergoing treatment.
The Board’s swift action highlights the importance of maintaining rigorous quality control in the pharmaceutical supply chain.
